Immunocore Holdings plc (IMCR)
NASDAQ: IMCR · Real-Time Price · USD
36.02
+0.97 (2.77%)
At close: Aug 18, 2026, 4:00 PM EDT
36.20
+0.18 (0.50%)
After-hours: Aug 18, 2026, 5:56 PM EDT
Immunocore Holdings Revenue
In the year 2025, Immunocore Holdings had annual revenue of $400.02M with 28.95% growth.
Revenue (ttm)
$400.02M
Revenue Growth
+28.95%
P/S Ratio
4.31
Revenue / Employee
$822,090
Employees
524
Market Cap
1.85B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 400.02M | 89.81M | 28.95% |
| Dec 31, 2024 | 310.20M | 60.77M | 24.37% |
| Dec 31, 2023 | 249.43M | 215.75M | 640.71% |
| Dec 31, 2022 | 33.67M | -2.81M | -7.70% |
| Dec 31, 2021 | 36.48M | -4.69M | -11.39% |
| Dec 31, 2020 | 41.17M | 7.13M | 20.95% |
| Dec 31, 2019 | 34.04M | 3.91M | 12.98% |
| Dec 31, 2018 | 30.13M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Fortrea Holdings | 2.68B |
| Sarepta Therapeutics | 1.97B |
| Lakefront Biotherapeutics NV | 1.13B |
| Syndax Pharmaceuticals | 252.25M |
| AnaptysBio | 232.39M |
| Xencor | 104.97M |
| Zymeworks | 37.13M |
IMCR News
- 11 days ago - Immunocore price target raised to $43 from $40 at Morgan Stanley - TheFly
- 12 days ago - Immunocore Holdings Earnings Call Transcript: Q2 2026 - Transcripts
- 12 days ago - Immunocore Holdings Earnings release: Q2 2026 - Filings
- 12 days ago - Immunocore Holdings Quarterly report: Q2 2026 - Filings
- 12 days ago - Immunocore Holdings Slides: Q2 2026 - Filings
- 12 days ago - Immunocore reports second quarter financial results and provides a business update - GlobeNewsWire
- 13 days ago - Immunocore Holdings Slides: Corporate presentation - Filings
- 15 days ago - Immunocore price target raised to $35 from $34 at Mizuho - TheFly